SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Roger's 1998 Short Picks -- Ignore unavailable to you. Want to Upgrade?

To: Marconi who wrote (17294)2/4/1999 10:41:00 AM
From: Hank  Read Replies (1) | Respond to of 18691
 
ZONA is running due to analyst upgrades. They've upped their earnings projections for Vasoscam. The only problem is that Vasoscam hasn't been approved for sale yet either here or in Europe, so the upgrades are a joke. Short the hell out of it now if you can find shares to borrow.



To: Marconi who wrote (17294)2/4/1999 11:16:00 AM
From: Marconi  Respond to of 18691
 
ZONA--quick review. Nothing new. 'Revenues' were offsets for cost of FDA applications. I saw nothing new. I think it dubious whether Zonagen can obtain approval for Vasomax, and Viagra is proven effective and has made the market. ZONA continues to strike me as a solid short, except for possible temporary squeeze effects.
Best regards,
m


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News